FAQ: Lantern Pharma's Subsidiary Starlight Therapeutics FDA Clearance for GBM Combination Trial
Summary
What is the significance of the FDA clearance for Starlight Therapeutics?
The FDA clearance allows Starlight Therapeutics to initiate a Phase Ib/2a clinical trial for STAR-001 in combination with spironolactone for glioblastoma multiforme (GBM) patients, offering hope for a cancer with limited treatment options.
What is STAR-001 and how does it work?
STAR-001 is a brain-penetrant DNA-damaging agent designed to exploit DNA repair deficiencies through synthetic lethality, with its effect enhanced by spironolactone, which induces NER deficiency in tumor cells.
What are the designations STAR-001 has received from the FDA?
STAR-001 has received both Orphan Drug and Fast Track designations from the FDA, recognizing its potential to treat rare diseases and expedite its development and review.
How does Lantern Pharma’s AI platform contribute to this trial?
Lantern Pharma’s AI-driven RADR(R) platform is used to identify optimal patient populations and accelerate development timelines, leveraging machine learning and multiomic data to enhance the drug development process.
Where can I find more information about Lantern Pharma and this trial?
More information is available in the company’s newsroom at https://ibn.fm/LTRN and the full press release can be viewed at https://ibn.fm/8ndAq.
What is glioblastoma multiforme (GBM)?
Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with limited treatment options, making the development of new therapies like STAR-001 critically important.
What phase is the clinical trial in, and what will it evaluate?
The trial is in Phase Ib/2a and will evaluate the safety, tolerability, and preliminary efficacy of STAR-001 in combination with spironolactone for patients with recurrent GBM.
Who is involved in the development of STAR-001?
Lantern Pharma, through its wholly owned subsidiary Starlight Therapeutics, is developing STAR-001, utilizing its AI-driven RADR(R) platform and collaborating with world-class scientific advisors.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 137763